Ding Ning, Wang Xin, Weisskopf Marc G, Sparrow David, Schwartz Joel, Hu Howard, Park Sung Kyun
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
PLoS One. 2016 Sep 1;11(9):e0161472. doi: 10.1371/journal.pone.0161472. eCollection 2016.
Cumulative exposure to lead is associated with cardiovascular outcomes. Polymorphisms in the δ-aminolevulinic acid dehydratase (ALAD), hemochromatosis (HFE), heme oxygenase-1 (HMOX1), vitamin D receptor (VDR), glutathione S-transferase (GST) supergene family (GSTP1, GSTT1, GSTM1), apolipoprotein E (APOE),angiotensin II receptor-1 (AGTR1) and angiotensinogen (AGT) genes, are believed to alter toxicokinetics and/or toxicodynamics of lead.
We assessed possible effect modification by genetic polymorphisms in ALAD, HFE, HMOX1, VDR, GSTP1, GSTT1, GSTM1, APOE, AGTR1 and AGT individually and as the genetic risk score (GRS) on the association between cumulative lead exposure and incident coronary heart disease (CHD) events.
We used K-shell-X-ray fluorescence to measure bone lead levels. GRS was calculated on the basis of 22 lead-related loci. We constructed Cox proportional hazard models to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident CHD. We applied inverse probability weighting to account for potential selection bias due to recruitment into the bone lead sub-study.
Significant effect modification was found by VDR, HMOX1, GSTP1, APOE, and AGT genetic polymorphisms when evaluated individually. Further, the bone lead-CHD associations became larger as GRS increases. After adjusting for potential confounders, a HR of CHD was 2.27 (95%CI: 1.50-3.42) with 2-fold increase in patella lead levels, among participants in the top tertile of GRS. We also detected an increasing trend in HRs across tertiles of GRS (p-trend = 0.0063).
Our findings suggest that lead-related loci as a whole may play an important role in susceptibility to lead-related CHD risk. These findings need to be validated in a separate cohort containing bone lead, lead-related genetic loci and incident CHD data.
铅的累积暴露与心血管疾病结局相关。δ-氨基乙酰丙酸脱水酶(ALAD)、血色素沉着症(HFE)、血红素加氧酶-1(HMOX1)、维生素D受体(VDR)、谷胱甘肽S-转移酶(GST)超基因家族(GSTP1、GSTT1、GSTM1)、载脂蛋白E(APOE)、血管紧张素II受体-1(AGTR1)和血管紧张素原(AGT)基因的多态性被认为会改变铅的毒代动力学和/或毒效动力学。
我们评估了ALAD、HFE、HMOX1、VDR、GSTP1、GSTT1、GSTM1、APOE、AGTR1和AGT基因的遗传多态性单独以及作为遗传风险评分(GRS)对累积铅暴露与冠心病(CHD)事件之间关联的可能效应修正作用。
我们使用K壳层X射线荧光法测量骨铅水平。GRS基于22个与铅相关的基因座计算得出。我们构建Cox比例风险模型来计算CHD事件的校正风险比(HR)和95%置信区间(CI)。我们应用逆概率加权法来处理因纳入骨铅亚研究而导致的潜在选择偏倚。
单独评估时,发现VDR、HMOX1、GSTP1、APOE和AGT基因多态性具有显著的效应修正作用。此外,随着GRS增加,骨铅与CHD的关联变得更强。在调整潜在混杂因素后,在GRS最高三分位数的参与者中,髌骨铅水平增加2倍时,CHD的HR为2.27(95%CI:1.50 - 3.42)。我们还检测到GRS三分位数间HR呈上升趋势(p趋势 = 0.0063)。
我们的研究结果表明,与铅相关的基因座整体可能在对铅相关CHD风险的易感性中起重要作用。这些结果需要在一个包含骨铅、与铅相关的基因座和CHD事件数据的独立队列中进行验证。